The drugs are being distributed by American Regent subsidiary and Animal Health Division.
The company’s decision follows the US food and Drug Administration’s (FDA) inspection and its meeting with its officials in connection with the distribution of those drugs.
Luitpold is in the process of developing a plan, in conjunction with outside consultants and the FDA, that will allow it to resume manufacturing and distribution of its drug products as soon as possible.
The company has further discussed with the FDA Drug Shortage Staff regarding this issue, and will work with them to address potential shortages of drug products critical to patient health.